
Colorectal Cancer
Latest News
Advertisement
Latest Videos

Advertisement
More News

Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).











Eric Van Cutsem, MD, PhD, discusses results from the phase IIIb CONSIGN study and the continuing advance of precision medicine in colorectal cancer.

James J. Lee, MD, PhD, discusses research into mismatch repair deficiency as a biomarker for PD-1 inhibition in colorectal cancer.











Guillem Argilés, MD, department of Medical Oncology, Vall d'Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
May’s GI Monthly Rewind: A Landmark Approval in CCA, Expanded Access for Daraxonrasib, and More Key Pipeline Updates
5















































































